ALK-Abelló Enters Tablet Supply Contract Expansion with Catalent

MT Newswires · 3d ago
11:13 AM EDT, 09/30/2026 (MT Newswires) -- ALK-Abelló (ALK-B.CO) extended its manufacturing agreement with Catalent to secure long-term supply for its sublingual immunotherapy tablet portfolio, according to a Wednesday release. The Danish specialty pharmaceutical company agreed to invest a total of 500 million Danish kroner in Catalent for long-term access to the contract development and manufacturing organization's Zydis tablet formulation technology for all its allergen products. The expanded deal also includes raising ALK's annual tablet production capacity in the UK and Canada by 300 million tablets to 1.1 billion tablets, starting in the early 2030s.